News
-
-
-
PRESS RELEASE
Biomind Labs Accelerates FDA Pathway for 5-MEO-DMT Candidate BMND08 with Proprietary Nano-Formulation as Patent Observations Are Successfully Withstood
Biomind Labs advances BMND08 into FDA-directed activities with newly engineered nano-formulation drug-delivery platform, strengthening patent position -
-
-
-
-
-
PRESS RELEASE
Biomind Labs Announces Filing of Continuous Disclosure Documents and Appointment of Scott Ackerman to the Board
Biomind Labs Inc. announces filing of continuous disclosure documents on SEDAR+ including management's discussion & analysis and officer certificates. Company appoints new independent director -